MDT

97.17

+2.33%↑

VEEV

295.69

+0.08%↑

A

141.95

+2.63%↑

HQY

90.19

-0.24%↓

PHR.US

23.94

+5.88%↑

MDT

97.17

+2.33%↑

VEEV

295.69

+0.08%↑

A

141.95

+2.63%↑

HQY

90.19

-0.24%↓

PHR.US

23.94

+5.88%↑

MDT

97.17

+2.33%↑

VEEV

295.69

+0.08%↑

A

141.95

+2.63%↑

HQY

90.19

-0.24%↓

PHR.US

23.94

+5.88%↑

MDT

97.17

+2.33%↑

VEEV

295.69

+0.08%↑

A

141.95

+2.63%↑

HQY

90.19

-0.24%↓

PHR.US

23.94

+5.88%↑

MDT

97.17

+2.33%↑

VEEV

295.69

+0.08%↑

A

141.95

+2.63%↑

HQY

90.19

-0.24%↓

PHR.US

23.94

+5.88%↑

Search

Ionis Pharmaceuticals Inc

Открыт

СекторЗдравоохранение

68.82 2.32

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

67.08

Макс.

68.97

Ключевые показатели

By Trading Economics

Доход

270M

124M

Продажи

320M

452M

Рентабельность продаж

27.331

Сотрудники

1,069

EBITDA

294M

150M

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

+13.31% upside

Рыночная статистика

By TradingEconomics

Рыночная капитализация

3.7B

10B

Предыдущая цена открытия

66.5

Предыдущая цена закрытия

68.82

Новостные настроения

By Acuity

50%

50%

149 / 371 Рейтинг в Healthcare

Техническая оценка

By Trading Central

Уверенность

Neutral Evidence

Ionis Pharmaceuticals Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

2 окт. 2025 г., 23:30 UTC

Популярные акции

Stocks to Watch: Rumble, Applied Materials, American Outdoor Brands

2 окт. 2025 г., 21:21 UTC

Отчет

Applied Materials Expects New Export Rule to Hit 2026 Revenue by $600 Million

3 окт. 2025 г., 00:00 UTC

Приобретения, слияния, поглощения

Warren Buffett's Berkshire Comes to the Aid of Occidental Petroleum -- Again -- WSJ

2 окт. 2025 г., 23:40 UTC

Обсуждения рынка

Gold Edges Higher, Aided by Risks U.S. Shutdown May Weaken Economy -- Market Talk

2 окт. 2025 г., 23:39 UTC

Обсуждения рынка

Japanese Stocks May Edge Higher, Tracking Wall Street Gains -- Market Talk

2 окт. 2025 г., 23:29 UTC

Приобретения, слияния, поглощения

Vistra: Transaction Remains on Track to Close This Qtr or 1Q 2026 >VST

2 окт. 2025 г., 23:29 UTC

Приобретения, слияния, поглощения

Vistra: Received Regulatory Approval From FERC for Acquisition of Certain Subsidiaries Owning Seven Natural-Gas Generation Facilities From Lotus Infrastructure Partners >VST

2 окт. 2025 г., 23:29 UTC

Приобретения, слияния, поглощения

Vistra: Next Step in Acquisition of Gas Generation Fleet With Approval From Federal Energy Regulatory Commission

2 окт. 2025 г., 23:00 UTC

Обсуждения рынка

Warehouse Needs Time to Restore Credibility With Investors -- Market Talk

2 окт. 2025 г., 22:54 UTC

Обсуждения рынка
Приобретения, слияния, поглощения

Scales's JV Buyout Lauded by Bull -- Market Talk

2 окт. 2025 г., 22:54 UTC

Обсуждения рынка
Приобретения, слияния, поглощения

Global Forex and Fixed Income Roundup: Market Talk

2 окт. 2025 г., 22:46 UTC

Обсуждения рынка

Synlait Milk Loses Bear Following Sale of North Island Assets -- Market Talk

2 окт. 2025 г., 22:46 UTC

Обсуждения рынка

Global Equities Roundup: Market Talk

2 окт. 2025 г., 21:17 UTC

Приобретения, слияния, поглощения

Buffett Scores Win in Berkshire's Deal for Occidental Chemicals Unit -- Barrons.com

2 окт. 2025 г., 20:50 UTC

Обсуждения рынка
Приобретения, слияния, поглощения

Energy & Utilities Roundup: Market Talk

2 окт. 2025 г., 20:50 UTC

Обсуждения рынка

Basic Materials Roundup: Market Talk

2 окт. 2025 г., 20:49 UTC

Приобретения, слияния, поглощения

OpenAI's Latest Funding Deal Returns Focus to AI Economy, Lifting U.S. Stocks -- WSJ

2 окт. 2025 г., 20:00 UTC

Приобретения, слияния, поглощения

Legrand Signs Definitive Agreement To Acquire Avtron Power Solutions, A Global Provider Of Load Banks & Power Quality Solutions >LR.FR

2 окт. 2025 г., 19:20 UTC

Обсуждения рынка

Natural Gas Snaps Winning Streak Despite Small Inventory Rise -- Market Talk

2 окт. 2025 г., 19:10 UTC

Обсуждения рынка

Bank of Canada to Publish Inflation Dashboard in 2026 -- Market Talk

2 окт. 2025 г., 19:04 UTC

Обсуждения рынка

Oil Futures Extend Losses as Markets Brace for Higher Output -- Market Talk

2 окт. 2025 г., 18:46 UTC

Приобретения, слияния, поглощения

Honeywell: Transaction Expected to Improve Annual Free Cash Flow by More Than $100 M Over Next Several Years and Then Decrease Over Time >HON

2 окт. 2025 г., 18:46 UTC

Приобретения, слияния, поглощения

Honeywell: Loss Will Be Excluded From Adjusted EPS >HON

2 окт. 2025 г., 18:46 UTC

Приобретения, слияния, поглощения

Honeywell: Estimated Impact of Divestiture Will Be One-Time Loss of About $115 M >HON

2 окт. 2025 г., 18:45 UTC

Приобретения, слияния, поглощения

Honeywell Will Have No Further Fincl Exposure to the Transferred Liabilities >HON

2 окт. 2025 г., 18:45 UTC

Приобретения, слияния, поглощения

Honeywell Utilized Portion of Cash From Resideo Indemnification and Reimbursement Agreement Termination to Fund Delticus Transaction >HON

2 окт. 2025 г., 18:44 UTC

Приобретения, слияния, поглощения

Honeywell: Delticus Assumed Full Responsibility for Administering and Resolving All Current and Future Asbestos-Related Claims >HON

2 окт. 2025 г., 18:44 UTC

Приобретения, слияния, поглощения

Honeywell and Delticus Contributed About $1.68 B in Cash, as Well as Certain Insurance Assets Related to Legacy Asbestos Liabilities >HON

2 окт. 2025 г., 18:44 UTC

Приобретения, слияния, поглощения

Honeywell: Transaction Strengthens Annual Free Cash Flow Generation >HON

2 окт. 2025 г., 18:43 UTC

Приобретения, слияния, поглощения

Honeywell Divested All Legacy Bendix Asbestos Liabilities, as Well as Certain Non-Bendix Asbestos Liabilities, to Delticus >HON

Сравнение c конкурентами

Изменение цены

Ionis Pharmaceuticals Inc Прогноз

Целевая цена

By TipRanks

13.31% рост

Прогноз на 12 месяцев

Средняя 74.56 USD  13.31%

Максимум 116.76 USD

Минимум 43 USD

Основано на мнении 21 аналитиков Wall Street, спрогнозировавших целевые цены для Ionis Pharmaceuticals Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

21 ratings

16

Покупка

5

Удержание

0

Продажа

Техническая оценка

By Trading Central

29.78 / 33.645Поддержка и Сопротивление

Краткосрочная

Neutral Evidence

Среднесрочная

Very Strong Bullish Evidence

Долгосрочная

Bearish Evidence

Настроения

By Acuity

149 / 371Рейтинг в Здравоохранение

Новостные настроения

Neutral

Волатильность

Ниже среднего

Объем новостей (RCV)

Ниже среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.
help-icon Live chat